Sort   by:  
 Page size 
UnknownDynamic single-cell systemic immune responses in immunotherapy-treated early-stage HR+ breast cancer patients.
Not available
S-EPMC12229575 | biostudies-literature
UnknownCellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer.
Not available
S-EPMC12663104 | biostudies-literature
UnknownA prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer.
Not available
S-EPMC9091255 | biostudies-literature
UnknownSomatic and Germline Genomic Alterations in Very Young Women with Breast Cancer.
Not available
S-EPMC9359721 | biostudies-literature
UnknownThe Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Not available
S-EPMC8815415 | biostudies-literature
UnknownThe Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.
Not available
S-EPMC6677598 | biostudies-literature
UnknownImpact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study.
Not available
S-EPMC12314373 | biostudies-literature
UnknownImpact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.
Not available
S-EPMC8598376 | biostudies-literature
UnknownHER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.
Not available
S-EPMC10977978 | biostudies-literature
UnknownAssessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.
Not available
S-EPMC10141272 | biostudies-literature
Sort   by:  
 Page size